Kommentar zu „177Lu-PSMA-617 beim metastasierten, kastrationsresistenten Prostatakarzinom“

Jan Philipp Radtke; Peter Albers; Frederik Lars Giesel

doi:10.1055/a-1707-6928

Aktuelle Urologie, Table of Contents

Aktuelle Urol 2022; 53(02): 106-110
DOI: 10.1055/a-1707-6928

Referiert und kommentiert

Kommentar zu „¹⁷⁷Lu-PSMA-617 beim metastasierten, kastrationsresistenten Prostatakarzinom“

Contributor(s):

Jan Philipp Radtke

¹Klinik für Urologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Deutschland

²Abteilung Radiologie, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland

,

Peter Albers

³Klinik für Urologie, Universität Düsseldorf, Düsseldorf, Deutschland

,

Frederik Lars Giesel

⁴Klinik für Nuklearmedizin, Universität Düsseldorf, Düsseldorf, Deutschland

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Sartor O, de Bono JS, Chi KN. et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2021;
2 Fizazi K, Herrmann K, Krause BJ. et al. 576MO - Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2021; 32: S626-S677
3 Yadav MP, Ballal S, Tripathi M. et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 2017;
4 Hofman MS, Violet J, Hicks RJ. et al. [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19: 825-833
5 Hadaschik B, Herrmann K. Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2021; 80: 520-521
6 Gillessen S, Attard G, Beer TM. et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]. Eur Urol 2020; 77: 508-547
7 Kratochwil C, Giesel FL, Eder M. et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 987-988
8 Kratochwil C, Giesel FL, Stefanova M. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J Nucl Med 2016; 57: 1170-1176
9 Hofman MS, Emmett L, Sandhu S. et al. 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP. Lancet 2021; 397: 797-804
10 Mottet N, Bellmunt J, Briers E. et al. EAU Guidelines on Prostate Cancer. Edn Present EAU Annu Congr Milan 2021.. Accessed January 01, 2021 at: http://www.uroweb.org/fileadmin/tx_eauguidelines/2005/Pocket/Prostate_Cancer.pdf
11 Gafita A, Calais J, Grogan TR. et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 2021; 22: 1115-1125